retatrutide study news Retatrutide—A Game Changer in Obesity Pharmacotherapy A network meta-analysis backed weight-loss

Vyvgart Hytrulo represents the first novel, precision mechanism of action in more than 30 years for CIDP, a rare, debilitating neuromuscular disorder of the peripheral nervous system, according to argenxs press release

These treatments should be offered to adults who meet all of the following: At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) BMI of 35 kg/m or above (or 32.5 kg/m or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) Access to a specialist weight management service that provides multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions Treatment is typically time-limited to up to 2 years Previous unsuccessful attempts at weight loss through lifestyle measures alone Orlistat may be considered for adults with a BMI of 28 kg/m or above with associated risk factors (such as type 2 diabetes or cardiovascular disease), or 30 kg/m or above without additional risk factors

PubMed Sanyal AJ, et al

Some lose 5% and stay there, but their blood pressure normalizes and they stop two of their three diabetes meds

Administration Requirements and Complexity Oral semaglutide has strict administration requirements that affect convenience

Spacing meals appropriately allows adequate digestion time, though this should be individualised to your treatment goals and comfort